Aurinia Pharmaceuticals Announced An Oral Presentation At The European Alliance Of Associations For Rheumatology 2024 In Vienna, Austria June 12-15, Which Includes Safety And Efficacy Profile Of Lupkynis For People With Lupus Nephritis
Portfolio Pulse from Benzinga Newsdesk
Aurinia Pharmaceuticals announced an upcoming oral presentation at the European Alliance of Associations for Rheumatology 2024 in Vienna, Austria, from June 12-15. The presentation will cover the safety and efficacy profile of Lupkynis for people with lupus nephritis.
June 05, 2024 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aurinia Pharmaceuticals will present data on Lupkynis at the European Alliance of Associations for Rheumatology 2024, focusing on its safety and efficacy for lupus nephritis.
The presentation at a major medical conference could increase visibility and credibility for Lupkynis, potentially boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100